Interplay between ER and TGF-b in carcinogenesis
Interplay between ER and TGF-b in carcinogenesis
批准号:
9181828
负责人:
Yong Wan
金额:
$38.2万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2021-06-30
关键词:
AddressApoptosisAttenuatedAutomobile DrivingBreast Cancer CellBreast CarcinogenesisCell divisionCellsDNA DamageDataDevelopmentDrug resistanceDrug usageEnsureEstrogen AntagonistsEstrogen ReceptorsEstrogensExhibitsGKLF proteinGoalsGrowthHumanLeadMalignant NeoplasmsMammary NeoplasmsMediatingModelingMolecularNew AgentsOncogenicPathway interactionsPatientsPharmaceutical PreparationsPlayProteolysisReceptor SignalingRecurrenceRegulationRegulation of ProteolysisResistanceRoleSignal TransductionSystemTGF Beta Signaling PathwayTamoxifenTestingThe Cancer Genome AtlasTherapeuticTherapeutic InterventionTransforming Growth Factor betaTumor Cell InvasionUbiquitinUp-RegulationXenograft procedurebeta-Transducin Repeat-Containing Proteinscancer stem cellcarcinogenesisclinically relevanthormone therapyin vivoinhibitor/antagonistmalignant breast neoplasmmouse modelmulticatalytic endopeptidase complexneoplastic cellnovelnovel strategiesresponseself-renewaltargeted treatmenttumortumor initiationtumor progressiontumorigenesisubiquitin-protein ligase
中文摘要
雌激素受体和转化生长因子-β在肿瘤发生中的相互作用
靶向治疗使包括乳腺癌在内的各种癌症的存活率有所提高。一个
靶向治疗的关键挑战是耐药性和复发的发展。
因此,确定激活代偿通路和
迫切需要进一步开发新的药物来协同靶向治疗。
该提案旨在确定KLF4(Krüppel-like factor4)蛋白降解的影响
协调雌激素或转化生长因子-β在乳腺肿瘤起始/侵袭中启动的信号转导,AS
以及对内分泌治疗的抵抗力。我们和其他人最近的研究揭示了KLF4
成为调节雌激素受体信号和转化生长因子-β信号的新角色
途径,以及其放松管制导致肿瘤形成和耐药性。我们
研究表明,在对雌激素的反应中,KLF4的上调是由于抑制
受E3连接酶VHL/VBC调控的KLF4周转促进雌激素诱导的有丝分裂
成长。我们还观察到,在对他莫昔芬耐药的乳腺癌细胞中,
KLF4由于补偿激活而抑制KLF4的降解
致癌的转化生长因子-β信号减弱他莫昔芬的反应。我们进一步观察到,虽然
β-TRCP/SCF通过破坏KLF4水平介导雌激素反应
在其E3连接酶VHl中,转化生长因子-β激活的Src通过促进KLF4的积累而诱导KLF4的积累
VHL的降解,进而拮抗他莫昔芬的反应。这样做的目的是
项目是确定泛素-蛋白酶体系统调节的机制
雌激素诱导的KLF4积聚,确保雌激素反应,并通过它
补偿性转化生长因子-β激活sRc通过以下途径抵消他莫昔芬的反应
抑制VHL介导的KLF4降解。此应用程序的最终目标是
确定KLF4蛋白降解调节在乳腺肿瘤起始/侵袭中的临床意义
和抗雌激素耐药,并进一步验证我们新的治疗干预
开发KLF4抑制剂以挽救他莫昔芬耐药性。我们的具体目标是
以下:(1)确定泛素降解机制如何协调雌激素-
诱导KLF4积聚;(2)确定KLF4-VHL/VBC轴的失调
导致增强癌症干细胞的自我更新,乳腺癌的启动/进展,以及
有助于抵抗雌激素;以及(3)确定放松管制对
KLF4-VHL/VBC轴在乳腺癌发生/侵袭中的作用及疗效验证
KLF4抑制剂对小鼠抗雌激素抵抗的干预作用。
英文摘要
Interplay between ER and TGF-β in carcinogenesis
Targeted therapies have benefited survival from various cancers, including breast cancer. A
critical challenge of targeted therapies is the development of drug resistance and recurrence.
Thus, identification of mechanisms underlying the activation of compensatory pathways and
further development of new agents that synergize the targeted therapies are urgently needed.
This proposal seeks to determine the impact of KLF4 (Krüppel-like factor 4) proteolysis that
orchestrates the signaling initiated by estrogen or TGF-β in breast tumor initiation/invasion, as
well as resistance to endocrine therapy. Recent studies by us and others have revealed KLF4
to be a novel player that regulates estrogen receptor signaling as well as TGF-β signaling
pathways, and whose deregulation leads to tumorigenesis and drug resistance. We
demonstrated that in response to estrogen, upregulation of KLF4 due to the suppression of
KLF4 turnover governed by the E3 ligase VHL/VBC facilitates estrogen-induced mitogenic
growth. We also observed in tamoxifen-resistant breast cancer cells that the accumulated
KLF4 due to the inhibition of KLF4 degradation because of the compensatory activation of
oncogenic TGF-β signaling attenuates the tamoxifen response. We further observed that while
β-TRCP/SCF mediates estrogen response through the elevation of KLF4 levels by destruction
of its E3 ligase VHL, TGF-β-activated Src induces accumulation of KLF4 via promoting the
degradation of VHL, which in turn antagonizes the tamoxifen response. The objective of this
project is to determine the mechanism by which the ubiquitin-proteasome system regulates
estrogen-induced KLF4 accumulation that ensures estrogen response, and by which the
activation of Src by compensatory TGF-β counteracts the tamoxifen response through
suppression of VHL-mediated KLF4 degradation. The ultimate goal of this application is to
identify the clinical relevance of KLF4 proteolytic regulation in breast tumor initiation/invasion
and anti-estrogen resistance, and further validate the therapeutic intervention of our newly
developed KLF4 inhibitor in the rescue of tamoxifen resistance. Our Specific Aims are the
following: (1) to determine how the ubiquitin degradation machinery orchestrates estrogen-
induced KLF4 accumulation; (2) to determine how dysregulation of the KLF4-VHL/VBC axis
leads to enhanced self-renewal of cancer stem cell, breast tumor initiation/progression, and
contributes to anti-estrogen resistance; and (3) to determine the impact of deregulation of the
KLF4-VHL/VBC axis in breast tumor initiation/invasion, and to validate the therapeutic
intervention of KLF4 inhibitor in the rescue of anti-estrogen resistance using murine models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10359179
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10361572
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting Posttranslational Modifications in Breast Carcinogenesis
-
批准号:10365966
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10523400
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting Posttranslational Modifications in Breast Carcinogenesis
-
批准号:10523396
-
项目类别:
-
资助金额:$46.22万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10184613
-
项目类别:
-
资助金额:$65.92万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10181635
-
项目类别:
-
资助金额:$52.25万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:10523253
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10523388
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:9655714
-
项目类别:
-
资助金额:$26.11万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:9512889
-
项目类别:
-
资助金额:$12.2万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9977693
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:10084161
-
项目类别:
-
资助金额:$8.12万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9181842
-
项目类别:
-
资助金额:$38.06万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9564343
-
项目类别:
-
资助金额:$25.99万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8657891
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8458491
-
项目类别:
-
资助金额:$29.01万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8838727
-
项目类别:
-
资助金额:$30.82万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8184804
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8296553
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: